552 related articles for article (PubMed ID: 26724382)
1. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
[TBL] [Abstract][Full Text] [Related]
2. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
Lam AM; Murakami E; Espiritu C; Steuer HM; Niu C; Keilman M; Bao H; Zennou V; Bourne N; Julander JG; Morrey JD; Smee DF; Frick DN; Heck JA; Wang P; Nagarathnam D; Ross BS; Sofia MJ; Otto MJ; Furman PA
Antimicrob Agents Chemother; 2010 Aug; 54(8):3187-96. PubMed ID: 20516278
[TBL] [Abstract][Full Text] [Related]
3. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
[TBL] [Abstract][Full Text] [Related]
4. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
Tong X; Le Pogam S; Li L; Haines K; Piso K; Baronas V; Yan JM; So SS; Klumpp K; Nájera I
J Infect Dis; 2014 Mar; 209(5):668-75. PubMed ID: 24154738
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.
Lam AM; Espiritu C; Bansal S; Micolochick Steuer HM; Zennou V; Otto MJ; Furman PA
J Virol; 2011 Dec; 85(23):12334-42. PubMed ID: 21957306
[TBL] [Abstract][Full Text] [Related]
6. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
[TBL] [Abstract][Full Text] [Related]
7. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
Chase R; Skelton A; Xia E; Curry S; Liu S; McMonagle P; Huang HC; Tong X
Antiviral Res; 2009 Nov; 84(2):178-84. PubMed ID: 19747948
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
Yang H; Robinson M; Corsa AC; Peng B; Cheng G; Tian Y; Wang Y; Pakdaman R; Shen M; Qi X; Mo H; Tay C; Krawczyk S; Sheng XC; Kim CU; Yang C; Delaney WE
Antimicrob Agents Chemother; 2014; 58(2):647-53. PubMed ID: 23939899
[TBL] [Abstract][Full Text] [Related]
9. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
[TBL] [Abstract][Full Text] [Related]
11. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.
Lam AM; Espiritu C; Bansal S; Micolochick Steuer HM; Niu C; Zennou V; Keilman M; Zhu Y; Lan S; Otto MJ; Furman PA
Antimicrob Agents Chemother; 2012 Jun; 56(6):3359-68. PubMed ID: 22430955
[TBL] [Abstract][Full Text] [Related]
12. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
Lenz O; Verbinnen T; Lin TI; Vijgen L; Cummings MD; Lindberg J; Berke JM; Dehertogh P; Fransen E; Scholliers A; Vermeiren K; Ivens T; Raboisson P; Edlund M; Storm S; Vrang L; de Kock H; Fanning GC; Simmen KA
Antimicrob Agents Chemother; 2010 May; 54(5):1878-87. PubMed ID: 20176898
[TBL] [Abstract][Full Text] [Related]
13. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.
Leumi S; Guo M; Lu J; Wang Z; Gan T; Han L; Ngari J; Tong Y; Xiang X; Xie Q; Wang L; Zhong J
Antiviral Res; 2022 Jan; 197():105224. PubMed ID: 34864126
[TBL] [Abstract][Full Text] [Related]
15. In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.
Xu S; Doehle B; Rajyaguru S; Han B; Barauskas O; Feng J; Perry J; Dvory-Sobol H; Svarovskaia ES; Miller MD; Mo H
Antivir Ther; 2017; 22(7):587-597. PubMed ID: 28248189
[TBL] [Abstract][Full Text] [Related]
16.
Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
[TBL] [Abstract][Full Text] [Related]
17. Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661.
Furman PA; Murakami E; Niu C; Lam AM; Espiritu C; Bansal S; Bao H; Tolstykh T; Micolochick Steuer H; Keilman M; Zennou V; Bourne N; Veselenak RL; Chang W; Ross BS; Du J; Otto MJ; Sofia MJ
Antiviral Res; 2011 Aug; 91(2):120-32. PubMed ID: 21600932
[TBL] [Abstract][Full Text] [Related]
18. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.
Mathy JE; Ma S; Compton T; Lin K
Antimicrob Agents Chemother; 2008 Sep; 52(9):3267-75. PubMed ID: 18591281
[TBL] [Abstract][Full Text] [Related]
19. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
[TBL] [Abstract][Full Text] [Related]
20. Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.
Dufner-Beattie J; O'Guin A; O'Guin S; Briley A; Wang B; Balsarotti J; Roth R; Starkey G; Slomczynska U; Noueiry A; Olivo PD; Rice CM
Antimicrob Agents Chemother; 2014 Jun; 58(6):3399-410. PubMed ID: 24709254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
